Shionogi Inc. v. Aurobindo Pharma Ltd.
1:17-cv-00072
Overview
Parties
Defendant
Qingdao Baheal Pharmaceutical Co. Ltd. Operating Company
Represented By
1 Attorneys ListedMorris James LLP
500 Delaware Avenue, Suite 1500, P.O. Box 2306
Aurobindo Pharma Ltd. Operating Company
Represented By
2 Attorneys ListedConnolly Gallagher LLP
1201 North Market Street, 20th Floor, Wilmington, DE 19801
Aurobindo Pharma USA, Inc. Operating Company
Represented By
2 Attorneys ListedConnolly Gallagher LLP
1201 North Market Street, 20th Floor, Wilmington, DE 19801
Plaintiff
Shionogi Inc. Operating Company
Represented By
3 Attorneys ListedBayard, P.A.
Bayard, P.A., 600 N. King Street
Counter Claimant
Andrx Labs, L.L.C. Operating Company
Represented By
2 Attorneys ListedBayard, P.A.
Bayard, P.A., 600 N. King Street
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 11 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 6,790,459 B1 Asserted | US Continuation / Sibling | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 1,991,078 A | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 1,335,708 A4 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 6,013,969 A | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 1,723,948 A1 | European Counterpart (EP) | View Official Patent → |
| π―π΅ Japan | JP 2002538912 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 2004531463 A | Japan Counterpart | View Official Patent → |
| π°π· South Korea | KR 2003006139 | South Korea Counterpart | View Official Patent → |
| π¨π¦ Canada | CA 002427195 A | Canada Counterpart | View Official Patent → |
| π¨π¦ Canada | CA 2427195 C | Canada Counterpart | View Official Patent → |
| π PCT International (WIPO) | WO 2002036100 A1 | PCT World Application | View Official Patent → |
Aurobindo Pharma USA Inc. v. Andrx Labs, LLC et al.
Aurobindo Pharma USA Inc. et al. v. Andrx Labs, LLC et al.
Aurobindo Pharma USA Inc. et al. v. Andrx Labs, LLC et al.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6790459
Methods for treating diabetes via administration of controlled release metformin
|
Filed: 2000-11-03
Issued: 2004-09-14
|
Expired (Term Ended)
+134d PTA
Expires: 2021-03-17
|
|
|
US6866866
Controlled release metformin compositions
|
Filed: 2000-11-03
Issued: 2005-03-15
|
Expired (Term Ended)
+162d PTA
Expires: 2021-04-14
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
33
Dispositive
11
Granted
6
Denied
2
Pending / Review
22
Motions by Category
Key Dispositive Motions & Rulings